{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T12:44:51Z","timestamp":1771332291832,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Minimal change disease is a common cause of nephrotic syndrome in adults. Higher relapse rate put patients at risk of steroids toxicity due to long-term exposure. Rituximab has been suggested to maintain long time remission and withdraw steroids and other immunosuppressants with fewer adverse events. However, optimal dose and dosing interval have not been explored.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Twenty-five patients were enrolled from 2017-10 to 2020-03 in Nanfang Hospital in China. Clinical and biological data were extracted from medical records and laboratory databases. Therapy composed of 375mg\/m<jats:sup>2<\/jats:sup> rituximab once three weeks for 3 dose and corticosteroid was applied. Complete remission was defined as reduction of proteinuria to 0.3g\/d. Remission rate, relapse rate, steroids used before and after rituximab therapy and adverse effects were documented at a mean time of 14.71 months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Twenty-two patients achieved complete remission for an average of 3.26 months and only 3 patients experienced one relapse respectively during the follow-up period. The mean remission maintenance time was 11.6 months, and was 5 months after steroids withdrawal. Steroids dose at last follow-up was 6.09mg\/d, which was significantly reduced compared to 28.15mg\/d before rituximab. Relapse rate before and after rituximab was 1.43 and 0.1, respectively. Only four minor adverse events were recorded.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Therapy consisted of 375mg\/m<jats:sup>2<\/jats:sup> rituximab once three weeks for 3 dose combined with corticosteroid is effective in inducing remission in adult patients with minimal change disease. Both of the relapse rate and dose of steroids used are significantly decreased with fewer side effects.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-021-02437-4","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T11:02:56Z","timestamp":1625137376000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Extended infusion of rituximab combined with steroids is effective in inducing remission and reducing relapse in adult minimal change disease"],"prefix":"10.1186","volume":"22","author":[{"given":"Diankun","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhanmei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng","family":"Nie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianxiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjuan","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guobao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Ai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,1]]},"reference":[{"key":"2437_CR1","first-page":"987","volume-title":"The kidney","author":"PH Nachman","year":"2008","unstructured":"Nachman PH, Jennette JC, Falk RJ. Primary glomerular disease. In: Brenner BM, editor. The kidney. 8th ed. Philadelphia: Saunders Elsevier; 2008. p. 987\u20131066.","edition":"8"},{"key":"2437_CR2","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1016\/S0140-6736(16)00272-5","volume":"387","author":"J Floege","year":"2016","unstructured":"Floege J, Amann K. Primary glomerulonephritides. Lancet. 2016;387:2036\u201348.","journal-title":"Lancet."},{"key":"2437_CR3","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2215\/CJN.05000516","volume":"12","author":"M Vivarelli","year":"2017","unstructured":"Vivarelli M, Massella L, Ruggiero B, Emma F. Minimal change disease. Clin J Am Soc Nephrol. 2017;12:332\u201345.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2437_CR4","doi-asserted-by":"publisher","first-page":"911","DOI":"10.2215\/CJN.01920219","volume":"14","author":"SM Korbet","year":"2019","unstructured":"Korbet SM, Whittier WL. Management of adult minimal change disease. Clin J Am Soc Nephrol. 2019;14:911\u20133.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2437_CR5","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2215\/CJN.03531006","volume":"2","author":"M Waldman","year":"2007","unstructured":"Waldman M, Crew RJ, Valeri A, Busch J, Stokes B, Markowitz G, et al. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol. 2007;2:445\u201353.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2437_CR6","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/ki.2012.444","volume":"83","author":"H Munyentwali","year":"2013","unstructured":"Munyentwali H, Bouachi K, Audard V, Remy P, Lang P, Mojaat R, et al. Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. Kidney Int. 2013;83:511\u20136.","journal-title":"Kidney Int"},{"issue":"6","key":"2437_CR7","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","volume":"90","author":"DG Maloney","year":"1997","unstructured":"Maloney DG, Grillo-L\u00f3 Pez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade Non-Hodgkin\u2019s Lymphoma. Blood. 1997;90(6):2188\u201395.","journal-title":"Blood."},{"key":"2437_CR8","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1007\/s00467-004-1434-z","volume":"19","author":"K Benz","year":"2004","unstructured":"Benz K, D\u00f6tsch J, Rascher W, Stachel D. Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol. 2004;19:794\u20137.","journal-title":"Pediatr Nephrol"},{"key":"2437_CR9","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s00467-008-0814-1","volume":"23","author":"V Guigonis","year":"2008","unstructured":"Guigonis V, Dallocchio A, Baudouin V, Dehennault M, Hachon-Le Camus C, Afanetti M, et al. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol. 2008;23:1269\u201379.","journal-title":"Pediatr Nephrol"},{"key":"2437_CR10","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s00467-009-1191-0","volume":"24","author":"K Kamei","year":"2009","unstructured":"Kamei K, Ito S, Nozu K, Fujinaga S, Nakayama M, Sako M, et al. Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol. 2009;24:1321\u20138.","journal-title":"Pediatr Nephrol"},{"key":"2437_CR11","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s00467-010-1465-6","volume":"25","author":"AL Sellier-Leclerc","year":"2010","unstructured":"Sellier-Leclerc AL, MacHer MA, Loirat C, Gu\u00e9rin V, Watier H, Peuchmaur M, et al. Rituximab efficiency in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2010;25:1109\u201315.","journal-title":"Pediatr Nephrol"},{"key":"2437_CR12","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.2215\/CJN.03470410","volume":"5","author":"A Gulati","year":"2010","unstructured":"Gulati A, Sinha A, Jordan SC, Hari P, Dinda AK, Sharma S, et al. Efficacy and safety of treatment with rituximab for difficult steroid-resistant and -dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol. 2010;5:2207\u201312.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2437_CR13","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1093\/ndt\/gfr548","volume":"27","author":"MJ Kemper","year":"2012","unstructured":"Kemper MJ, Gellermann J, Habbig S, Krmar RT, Dittrich K, Jungraithmayr T, et al. Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome. Nephrol Dial Transplant. 2012;27:1910\u20135.","journal-title":"Nephrol Dial Transplant"},{"key":"2437_CR14","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.2215\/CJN.09421010","volume":"6","author":"P Ravan","year":"2011","unstructured":"Ravan P, Magnasco A, Edefonti A, Murer L, Rossi R, Ghio L, et al. Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol. 2011;6:1308\u201315.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2437_CR15","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","volume":"384","author":"K Iijima","year":"2014","unstructured":"Iijima K, Sako DM, Nozu K, Mori R, Tuchida N, Kamei K, et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2014;384:1273\u201381.","journal-title":"Lancet."},{"key":"2437_CR16","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1007\/s00467-017-3746-9","volume":"33","author":"K Iijima","year":"2018","unstructured":"Iijima K, Sako M, Kamei K, Nozu K. Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials. Pediatr Nephrol. 2018;33:1449\u201355.","journal-title":"Pediatr Nephrol"},{"key":"2437_CR17","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12882-020-01797-7","volume":"21","author":"P Hansrivijit","year":"2020","unstructured":"Hansrivijit P, Cheungpasitporn W, Thongprayoon C, Ghahramani N. Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis. BMC Nephrol. 2020;21:134.","journal-title":"BMC Nephrol"},{"key":"2437_CR18","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.autrev.2017.04.007","volume":"16","author":"A Kronbichler","year":"2017","unstructured":"Kronbichler A, Windpessl M, Pieringer H, Jayne DRW. Rituximab for immunologic renal disease: what the nephrologist needs to know. Autoimmun Rev. 2017;16:633\u201343.","journal-title":"Autoimmun Rev"},{"key":"2437_CR19","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/nep.12744","volume":"21","author":"E Papakrivopoulou","year":"2016","unstructured":"Papakrivopoulou E, Shendi AM, Salama AD, Khosravi M, Connolly JO, Trompeter R. Effective treatment with rituximab for the maintenance of remission in frequently relapsing minimal change disease. Nephrology. 2016;21:893\u2013900.","journal-title":"Nephrology."},{"key":"2437_CR20","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1093\/ckj\/sfy067","volume":"12","author":"FB Cortazar","year":"2018","unstructured":"Cortazar FB, Rosenthal J, Laliberte K, Niles JL. Continuous B-cell depletion in frequently relapsing, steroid-dependent and steroid-resistant nephrotic syndrome. Clin Kidney J. 2018;12:224\u201331.","journal-title":"Clin Kidney J"},{"key":"2437_CR21","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1093\/ndt\/gfs515","volume":"28","author":"T Takei","year":"2013","unstructured":"Takei T, Itabashi M, Moriyama T, Kojima C, Shiohira S, Shimizu A, et al. Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults. Nephrol Dial Transplant. 2013;28:1225\u201332.","journal-title":"Nephrol Dial Transplant"},{"key":"2437_CR22","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s11255-012-0206-0","volume":"45","author":"WY Kong","year":"2013","unstructured":"Kong WY, Swaminathan R, Irish A. Our experience with rituximab therapy for adult-onset primary glomerulonephritis and review of literature. Int Urol Nephrol. 2013;45:795\u2013802.","journal-title":"Int Urol Nephrol"},{"key":"2437_CR23","doi-asserted-by":"publisher","first-page":"28799","DOI":"10.18632\/oncotarget.25612","volume":"9","author":"R Fenoglio","year":"2018","unstructured":"Fenoglio R, Sciascia S, Beltrame G, Mesiano P, Ferro M, Quattrocchio G, et al. Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome. Oncotarget. 2018;9:28799\u2013804.","journal-title":"Oncotarget."},{"key":"2437_CR24","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1093\/ndt\/gft312","volume":"29","author":"A Bruchfeld","year":"2014","unstructured":"Bruchfeld A, Benedek S, Hilderman M, Medin C, Snaedal-Jonsdottir S, Korkeila M. Rituximab for minimal change disease in adults: long-term follow-up. Nephrol Dial Transplant. 2014;29:851\u20136.","journal-title":"Nephrol Dial Transplant"},{"key":"2437_CR25","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1093\/ndt\/gfu209","volume":"29","author":"J Guitard","year":"2014","unstructured":"Guitard J, Hebral AL, Fakhouri F, Joly D, Daugas E, Rivalan J, et al. Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance. Nephrol Dial Transplant. 2014;29:2084\u201391.","journal-title":"Nephrol Dial Transplant"},{"key":"2437_CR26","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s40259-017-0221-x","volume":"31","author":"I DaSilva","year":"2017","unstructured":"DaSilva I, Huerta A, Quintana L, Redondo B, Iglesias E, Draibe J, et al. Rituximab for steroid-dependent or frequently relapsing idiopathic nephrotic syndrome in adults: a retrospective, multicenter study in Spain. BioDrugs. 2017;31:239\u201349.","journal-title":"BioDrugs"},{"key":"2437_CR27","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1681\/ASN.2013030251","volume":"25","author":"P Ruggenenti","year":"2014","unstructured":"Ruggenenti P, Ruggiero B, Cravedi P, Vivarelli M, Massella L, Maras\u00e0 M, et al. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J Am Soc Nephrol. 2014;25:850\u201363.","journal-title":"J Am Soc Nephrol"},{"key":"2437_CR28","doi-asserted-by":"publisher","first-page":"93438","DOI":"10.18632\/oncotarget.21833","volume":"8","author":"H Ren","year":"2017","unstructured":"Ren H, Lin L, Shen P, Li X, Xie J, Pan X, et al. Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis. Oncotarget. 2017;8:93438\u201343.","journal-title":"Oncotarget."},{"key":"2437_CR29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ckj\/sfx043","volume":"10","author":"C King","year":"2017","unstructured":"King C, Logan S, Smith SW, Hewins P. The efficacy of rituximab in adult frequently relapsing minimal change disease. Clin Kidney J. 2017;10:16\u20139.","journal-title":"Clin Kidney J"},{"key":"2437_CR30","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1111\/nep.13554","volume":"24","author":"R Ramachandran","year":"2019","unstructured":"Ramachandran R, Bharati J, Rao I, Kashif AW, Nada R, Minz R, et al. Persistent CD-19 depletion by rituximab is cost-effective in maintaining remission in calcineurin-inhibitor dependent podocytopathy. Nephrology. 2019;24:1241\u20137.","journal-title":"Nephrology."},{"key":"2437_CR31","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.2215\/CJN.05080610","volume":"5","author":"FC Fervenza","year":"2010","unstructured":"Fervenza FC, Abraham RS, Erickson SB, Irazabal MV, Eirin A, Specks U, et al. Rituximab therapy in idiopathic membranous nephropathy: A 2-year study. Clin J Am Soc Nephrol. 2010;5:2188\u201398.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2437_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/kisup.2012.1","volume":"2","author":"Kidney Disease Improving Global Outcomes","year":"2012","unstructured":"Kidney Disease Improving Global Outcomes. KDIGO Clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2012;2:1\u2013274.","journal-title":"Kidney Int Suppl"},{"key":"2437_CR33","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1681\/ASN.2016010093","volume":"27","author":"X Xu","year":"2016","unstructured":"Xu X, Wang G, Chen N, Lu T, Nie S, Xu G, et al. Long-term exposure to air pollution and increased risk of membranous nephropathy in China. J Am Soc Nephrol. 2016;27:3739\u201346.","journal-title":"J Am Soc Nephrol"},{"key":"2437_CR34","doi-asserted-by":"publisher","first-page":"85ra46","DOI":"10.1126\/scitranslmed.3002231","volume":"3","author":"A Fornoni","year":"2011","unstructured":"Fornoni A, Sageshima J, Wei C, Merscher-Gomez S, Aguillon-Prada R, Jauregui AN, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med. 2011;3:85ra46.","journal-title":"Sci Transl Med"},{"key":"2437_CR35","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1093\/ndt\/gfr405","volume":"27","author":"AL Sellier-Leclerc","year":"2012","unstructured":"Sellier-Leclerc AL, Baudouin V, Kwon T, MacHer MA, Gu\u00e9rin V, Lapillonne H, et al. Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood-follow-up after CD19 recovery. Nephrol Dial Transplant. 2012;27:1083\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"2437_CR36","doi-asserted-by":"publisher","first-page":"826","DOI":"10.4161\/mabs.26008","volume":"5","author":"J Golay","year":"2013","unstructured":"Golay J, Semenzato G, Rambaldi A, Fo\u00e0 R, Gaidano G, Gamba E, et al. Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. MAbs. 2013;5:826\u201337.","journal-title":"MAbs."},{"key":"2437_CR37","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1093\/ndt\/gfz041","volume":"34","author":"S Boyer-Suavet","year":"2019","unstructured":"Boyer-Suavet S, Andreani M, Cremoni M, Brglez V, Benzaken S, Bernard G, et al. Rituximab bioavailability in primary membranous nephropathy. Nephrol Dial Transplant. 2019;34:1423\u20135.","journal-title":"Nephrol Dial Transplant"},{"key":"2437_CR38","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jim.2017.09.001","volume":"451","author":"R Jacobs","year":"2017","unstructured":"Jacobs R, Langer-Jacobus T, Duong M, Stahl K, Haller H, Schmidt RE, et al. Detection and quantification of rituximab in the human urine. J Immunol Methods. 2017;451:118\u201321.","journal-title":"J Immunol Methods"},{"key":"2437_CR39","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1182\/blood-2005-04-1769","volume":"107","author":"F Perosa","year":"2006","unstructured":"Perosa F, Favoino E, Caragnano MA, Dammacco F. Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor. Blood. 2006;107:1070\u20137.","journal-title":"Blood."},{"key":"2437_CR40","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/nrneph.2016.147","volume":"12","author":"RJ Maas","year":"2016","unstructured":"Maas RJ, Deegens JK, Smeets B, Moeller MJ, Wetzels JF. Minimal change disease and idiopathic FSGS: manifestations of the same disease. Nat Rev Nephrol. 2016;12:768\u201376.","journal-title":"Nat Rev Nephrol"},{"key":"2437_CR41","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/S0140-6736(74)91880-7","volume":"304","author":"RJ Shalhoub","year":"1974","unstructured":"Shalhoub RJ. Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet. 1974;304:556\u201360.","journal-title":"Lancet."},{"key":"2437_CR42","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/ki.1991.232","volume":"40","author":"A Koyama","year":"1991","unstructured":"Koyama A, Fujisaki M, Kobayashi M, Igarashi M, Narita M. A glomerular permeability factor produced by human T cell hybridomas. Kidney Int. 1991;40:453\u201360.","journal-title":"Kidney Int"},{"key":"2437_CR43","doi-asserted-by":"publisher","first-page":"102671","DOI":"10.1016\/j.autrev.2020.102671","volume":"19","author":"P Gauckler","year":"2020","unstructured":"Gauckler P, Il SJ, Alberici F, Audard V, Bruchfeld A, Busch M, et al. Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown? Autoimmun Rev. 2020;19:102671.","journal-title":"Autoimmun Rev"},{"key":"2437_CR44","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1042\/CS20040095","volume":"107","author":"JG Van Den Berg","year":"2004","unstructured":"Van Den Berg JG, Weening JJ. Role of the immune system in the pathogenesis of idiopathic nephrotic syndrome. Clin Sci. 2004;107:125\u201336.","journal-title":"Clin Sci."},{"key":"2437_CR45","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jaut.2017.12.014","volume":"89","author":"A Jamin","year":"2018","unstructured":"Jamin A, Berthelot L, Couderc A, Chemouny JM, Boedec E, Dehoux L, et al. Autoantibodies against podocytic UCHL1 are associated with idiopathic nephrotic syndrome relapses and induce proteinuria in mice. J Autoimmun. 2018;89:149\u201361.","journal-title":"J Autoimmun"},{"key":"2437_CR46","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1158\/1541-7786.MCR-11-0154","volume":"9","author":"C Bezombes","year":"2011","unstructured":"Bezombes C, Fourni\u00e9 JJ, Laurent G. Direct effect of rituximab in B-cell-derived lymphoid neoplasias: Mechanism, regulation, and perspectives. Mol Cancer Res. 2011;9:1435\u201342.","journal-title":"Mol Cancer Res"},{"key":"2437_CR47","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1681\/ASN.2015060672","volume":"28","author":"SK Mallipattu","year":"2017","unstructured":"Mallipattu SK, Guo Y, Revelo MP, Roa-Pe\u00f1a L, Miller T, Ling J, et al. Kr\u00fcppel-like factor 15 mediates glucocorticoid-induced restoration of podocyte differentiation markers. J Am Soc Nephrol. 2017;28:166\u201384.","journal-title":"J Am Soc Nephrol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02437-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-021-02437-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02437-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T16:04:24Z","timestamp":1675526664000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-021-02437-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,1]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["2437"],"URL":"https:\/\/doi.org\/10.1186\/s12882-021-02437-4","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,1]]},"assertion":[{"value":"25 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Human Ethics Review Committee of Nanfang Hospital, Southern Medical University. Written informed consent was obtained from all patients prior to rituximab treatment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"242"}}